Navigation Links
Basketball Star Details His Struggle With Gout
Date:5/23/2008

Maurice Cheeks shows that the arthritic condition can strike anyone

FRIDAY, May 23 (HealthDay News) -- He's a 15-year veteran of the National Basketball Association, a four-time NBA All-Star, and head coach of the Philadelphia 76ers. He's basketball great Maurice Cheeks.

And he's got gout.

"I had no idea what gout was," Cheeks said, describing his first encounter -- at the age of 46 -- with the often-debilitating arthritic condition. "Never heard of it. Never talked to anyone about it, and then I started to find out that there were many other people with this condition."

Cheeks made his remarks at a press conference Thursday in New York City to mark the second annual National Gout Awareness Day, sponsored by the Gout & Uric Acid Education Society (GUAES). The goal is to draw attention to the risks, symptoms, and treatments associated with a condition that strikes between three million and five million adult Americans, and to debunk stereotypes about the so-called "disease of kings."

According to GUAES, gouty arthritis results from a condition known as hyperuricemia -- the build-up of abnormally high levels of uric acid in the blood. A normal waste product that forms from the breakdown of purines found in cells and a wide range of foods, uric acid is usually dissolved in the blood, passed through the kidney, and excreted through urine.

But in excess amounts, sodium urate can crystallize. In some cases, the resulting needle-like formations lodge and jab into joints, bringing about sudden and painful bouts of tenderness, redness, stiffness, and swelling in the big toe, instep, ankle, heel, knee, wrist, finger, or elbow.

People typically describe the pain as akin to the trauma of childbirth or breaking a bone.

"I don't think I can adequately express the pain," Cheeks said.

"I once had a severe ankle sprain, and in order for me to play, they had to wrap it and wrap
'/>"/>

Copyright©2008 ScoutNews,LLC.
All rights reserved  

Page: 1 2 3

Related medicine news :

1. Thousands of Womens Basketball Referees to Wear Pink Whistles February 8-17; Calling For a Cure Program to Raise Funds for Cancer Research
2. Sharing Miracles Television Program to Feature North Carolina State Womens Basketball Coach Kay Yow
3. CCH White Paper Details Subprime Crisis, Wider Effects
4. Labopharm announces details for first quarter results conference call and annual meeting
5. Study Details New Molecular Approach to Preventing Alzheimers
6. American Cancer Society report details cancer prevention efforts
7. Young Innovations, Inc. Provides First Quarter Conference Call Details
8. CryoLife Announces Release Date and Teleconference Call Details for First Quarter 2008 Financial Results
9. Study details cost-effectiveness of rheumatoid arthritis treatments for Medicare recipients
10. Haemacure Announces Details of its Annual General and Special Meeting of Shareholders
11. Hillenbrand Industries Announces Formal Board Approval of Separation by Means of Share Distribution and Details for Completion
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Basketball Star Details His Struggle With Gout 
Basketball Star Details His Struggle With Gout
Breaking Medicine Technology:BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 2BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 3BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 4Shanghai ChemPartner Is Pleased to be Part of Agios' Groundbreaking Cancer Research 2Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 2Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 3Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 4Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 5Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 6Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 7Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 8Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 9Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 10Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 11Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 12Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 13Andrews Institute for Orthopaedics and Sports Medicine Now Providing Free Orthopaedic Exams and Assessments on Saturday Mornings to Student Athletes 55929 1Andrews Institute for Orthopaedics and Sports Medicine Now Providing Free Orthopaedic Exams and Assessments on Saturday Mornings to Student Athletes 55929 2Andrews Institute for Orthopaedics and Sports Medicine Now Providing Free Orthopaedic Exams and Assessments on Saturday Mornings to Student Athletes 55929 3American Imaging Management Reacts to New England Journal of Medicine Articles on Diagnostic Imaging 55925 1American Imaging Management Reacts to New England Journal of Medicine Articles on Diagnostic Imaging 55925 2Trauma 411 3A Prolonged Surgery Should be Avoided in Certain Cases 4932 1Trauma 411 3A Prolonged Surgery Should be Avoided in Certain Cases 4932 2Trauma 411 3A Prolonged Surgery Should be Avoided in Certain Cases 4932 3
Other Medicine Technology:Data Reported at ICAAC Indicates Selzentry(TM) Phase III Treatment-Naive Trial Shows Increased Efficacy When Used With Enhanced Trofile(TM) Assay 2Data Reported at ICAAC Indicates Selzentry(TM) Phase III Treatment-Naive Trial Shows Increased Efficacy When Used With Enhanced Trofile(TM) Assay 3Data Reported at ICAAC Indicates Selzentry(TM) Phase III Treatment-Naive Trial Shows Increased Efficacy When Used With Enhanced Trofile(TM) Assay 4Data Reported at ICAAC Indicates Selzentry(TM) Phase III Treatment-Naive Trial Shows Increased Efficacy When Used With Enhanced Trofile(TM) Assay 5Data Reported at ICAAC Indicates Selzentry(TM) Phase III Treatment-Naive Trial Shows Increased Efficacy When Used With Enhanced Trofile(TM) Assay 6Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 2Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 3Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 4